STOCK TITAN
  1. Home
  2. News
  3. TSVT

2seventy bio Inc - TSVT STOCK NEWS

Welcome to our dedicated news page for 2seventy bio (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2seventy bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 2seventy bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 2seventy bio's position in the market.

News
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Rhea-AI Summary
Abecma receives FDA approval for earlier use in treating relapsed or refractory multiple myeloma, demonstrating significant progression-free survival benefits and a well-established safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
fda approval
-
News
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma. The company has transferred its oncology and autoimmune research programs to Regeneron, emphasizing a new strategic direction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.22%
Tags
none
-
News
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
Rhea-AI Summary
2seventy bio, Inc. (TSVT) appoints Eli Casdin and Charlie Newton as new independent members of the Board of Directors. Casdin Capital owns 2.3% of outstanding shares. The company aims for strategic re-alignment and enhancing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.91%
Tags
management
News
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Rhea-AI Summary
Bristol Myers Squibb and 2seventy bio announced positive FDA committee vote for Abecma in multiple myeloma treatment. Abecma's favorable benefit/risk profile was recognized based on KarMMa-3 study results. FDA review ongoing with no set action date yet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
News
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) reported financial results for Q4 and full year 2023, highlighting $56M U.S. commercial revenue in Q4 and $358M for the year. The company ended the quarter with $221.8M in cash, extending the cash runway beyond 2027. Abecma faced competition impacting Q4 sales, but upcoming milestones, like the ODAC meeting on March 15, 2024, offer growth potential. The company's strategic focus on Abecma includes a partnership with Bristol Myers Squibb and clinical successes with KarMMa-3 and KarMMa-2 studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
earnings
-
News
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
Rhea-AI Summary
2seventy bio, Inc. (TSVT) to announce Q4 and full year 2023 financial results on March 5, 2024. Management team to present at investor conferences. Earnings call scheduled for March 5, 2024, at 8:00 a.m. ET. Webcasts available for investor conference presentations and earnings call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.46%
Tags
conferences earnings
News
2seventy bio to Participate in Upcoming Investor Conferences
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) announced that its management team will present at upcoming investor conferences, including the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and Citi’s 2024 Virtual Oncology Leadership Summit. The presentations will be available via live webcast and archived for 30 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
News
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
Rhea-AI Summary
Bristol Myers Squibb and 2seventy bio, Inc. announced that the FDA will convene a virtual meeting of the Oncologic Drugs Advisory Committee to review data supporting the supplemental Biologics License Application for Abecma for triple-class exposed relapsed or refractory multiple myeloma. The meeting will focus on the secondary endpoint of overall survival from the pivotal Phase 3 KarMMa-3 study. Abecma has recently been approved in Japan and received a positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use of the European Medicines Agency for patients with triple-class exposed relapsed and refractory multiple myeloma after at least two prior therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
none
-
News
2seventy bio Announces New Strategic Path Forward
Rhea-AI Summary
2seventy bio, Inc. (TSVT) announced a strategic re-alignment to focus exclusively on the commercialization and development of Abecma, its BCMA-targeted CAR T therapy for multiple myeloma. The company expects annual cost savings of approximately $150 million in 2024 and $200 million in 2025, extending its cash runway beyond 2027. 2seventy bio will sell its R&D pipeline to Regeneron to launch Regeneron Cell Medicines business. Chip Baird is named the incoming CEO, and Nick Leschly is named the incoming Chairman of the Board of Directors. The company will focus on Abecma's growth commercially and return to potential third-line launch later this year. The company is taking actions to return Abecma to commercial growth in 2024, expanding its site footprint to enable more patients to access the treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.9%
Tags
none
News
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced results from the final progression-free survival (PFS) analysis of KarMMa-3, a Phase 3 study evaluating Abecma in adults with relapsed and refractory multiple myeloma. Abecma maintained a 51% reduction in risk of disease progression or death with a median PFS of 13.8 months compared to 4.4 months for standard regimens. The complete response rate was 44% vs. 5% for standard regimens. Abecma demonstrated deep and durable responses in newly-diagnosed multiple myeloma with a 77% complete response rate and no new safety signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Stock TSVT logo
2seventy bio Inc

NYSE:TSVT

TSVT Rankings

#3683 Ranked by Market Cap
#5421 Ranked by Stock Gains
N/A Ranked by Dividends

TSVT Stock Data

258.61M
49.61M
2.5%
98.41%
13.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About TSVT

we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer